Praxis Precision Medicines (PRAX) Cash from Financing Activities (2019 - 2026)

Praxis Precision Medicines' Cash from Financing Activities history runs 8 years deep, the most recent figure standing at $609.4 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 1022.98% year-over-year to $609.4 million; the TTM figure through Mar 2026 stood at $1.3 billion (up 225.87% YoY), while the FY2025 annual figure was $702.2 million, up 36.52% from the prior year.
• Cash from Financing Activities was $609.4 million for Q1 2026 at Praxis Precision Medicines, down from $612.5 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $612.5 million in Q4 2025 to a low of $504000.0 in Q2 2022.
• Historically, Cash from Financing Activities has averaged $120.5 million across 5 years, with a median of $23.3 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities tumbled 99.49% in 2022, then soared 13724.4% in 2023.
• A 5-year view of Cash from Financing Activities shows it stood at $5.4 million in 2022, then retreated by 23.41% to $4.1 million in 2023, then jumped by 2657.32% to $113.8 million in 2024, then surged by 438.4% to $612.5 million in 2025, then fell by 0.5% to $609.4 million in 2026.
• The last three Cash from Financing Activities figures came in at $609.4 million (Q1 2026), $612.5 million (Q4 2025), and $6.8 million (Q3 2025), per Business Quant data.